Effect of a novel DNA vaccine against pancreas disease caused by salmonid alphavirus subtype 3 in Atlantic salmon (Salmo salar)

Thorarinsson, Ragnar; Wolf, Jeffrey C.; Inami, Makoto; Phillips, Lisa; Jones, Ginny; Macdonald, Alicia M.; Rodrı́guez, José F.; Sindre, Hilde; Skjerve, Eystein; Rimstad, Espen; Evensen, Øystein

doi:10.1016/j.fsi.2020.12.002

Cited by 23 publications

(33 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fortunately, Clynav protects against weight loss, reduces the prevalence and severity of morphological tissue lesions within the cardia, pancreas and skeletal muscle, and reduces mortality for up to 1 year after vaccination. Additionally, when compared to a traditional monovalent vaccine, Clynav provided significantly higher neutralizing antibody titers, conferred lower viremia, reduced transmission to cohabitating naïve fish, and conferred a significantly higher weight gain post challenge (216). The major criticism of these DNA vaccines is the incorporation rate in the vaccinated subjects.…”

Section: Pancreas Disease -Clynavmentioning

confidence: 99%

Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines

et al. 2021

View full text Add to dashboard Cite

The success of inactivated and live-attenuated vaccines has enhanced livestock productivity, promoted food security, and attenuated the morbidity and mortality of several human, animal, and zoonotic diseases. However, these traditional vaccine technologies are not without fault. The efficacy of inactivated vaccines can be suboptimal with particular pathogens and safety concerns arise with live-attenuated vaccines. Additionally, the rate of emerging infectious diseases continues to increase and with that the need to quickly deploy new vaccines. Unfortunately, first generation vaccines are not conducive to such urgencies. Within the last three decades, veterinary medicine has spearheaded the advancement in novel vaccine development to circumvent several of the flaws associated with classical vaccines. These third generation vaccines, including DNA, RNA and recombinant viral-vector vaccines, induce both humoral and cellular immune response, are economically manufactured, safe to use, and can be utilized to differentiate infected from vaccinated animals. The present article offers a review of commercially available novel vaccine technologies currently utilized in companion animal, food animal, and wildlife disease control.

show abstract

Section: Pancreas Disease -Clynavmentioning

confidence: 99%

Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The improvement of immunogenicity and the easy efficient delivery of NA vaccines provide several rationales for NA vaccination of companion and production animals against classical and emerging veterinary virus diseases, as well as new zoonotic viruses. In general, plasmids seem cost-effective for veterinary use (as exemplified even for fish farming [19][20][21]). The stability of plasmid DNA is high and can be lyophilized, thus eliminating the need for cold chain.…”

Section: Veterinary Applicationsmentioning

confidence: 99%

“…The road to obtaining useful veterinary DNA vaccine candidates has been long but with many promising observations (Table 1), and a variety of veterinary NA vaccine candidates have undergone clinical trials over the years [22][23][24][25].The animal diseases most targeted by veterinarian NA vaccines include primarily viral diseases, e.g., foot and mouth disease and herpes virus infection in cattle, Aujeszky's disease and classical swine fever in swine, rabies and canine distemper in canines, and avian influenza, infectious bronchitis, infectious bursal disease, and coccidiosis in birds [22,23,[26][27][28][29] (Table 1). Fish DNA vaccines [19] for infectious hematopoietic necrosis virus was licensed in 2005 [20] and a DNA vaccine against salmon pancreas disease was licensed in 2016 [21], as further discussed below. In addition, promising DNA vaccine candidates against bacterial and protozoan infections, e.g., coccidiosis, were obtained when using the 3-1E and EtMIC2 genes combined with cytokines as adjuvants that protected birds from this economically important infection [30].…”

Section: Veterinary Applicationsmentioning

confidence: 99%

“…Three plasmid DNA vaccines for prevention of infectious diseases have received approval, including two for fish and one for horses. These included two for fish (salmon) [19]: one for infectious hematopoietic necrosis virus (in 2005) [20], and one for pancreas disease (in 2016) caused by salmon alphavirus subtype 3 [21]. An equine vaccine co-developed by the US CDC and Fort Dodge Animal Health against the West Nile virus (WNV) was licensed (in 2005) [39].…”

Section: Licensed Veterinary Plasmid Dna Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

The Key Role of Nucleic Acid Vaccines for One Health

Fomsgaard

Liu²

2021

Viruses

View full text Add to dashboard Cite

The ongoing SARS-CoV-2 pandemic has highlighted both the importance of One Health, i.e., the interactions and transmission of pathogens between animals and humans, and the potential power of gene-based vaccines, specifically nucleic acid vaccines. This review will highlight key aspects of the development of plasmid DNA Nucleic Acid (NA) vaccines, which have been licensed for several veterinary uses, and tested for a number of human diseases, and will explain how an understanding of their immunological and real-world attributes are important for their efficacy, and how they helped pave the way for mRNA vaccines. The review highlights how combining efforts for vaccine development for both animals and humans is crucial for advancing new technologies and for combatting emerging diseases.

show abstract

“…As an alternative approach, some studies have focused on developing DNA vaccines [193][194][195]. To date, two DNA vaccines have been licensed for use in aquaculture, one against IHN in Canada [194,196], while the other is against pancreas disease (PD) in Norway [197]. Most fish vaccines are administered by injection, which is labor intensive if done by human vaccinators, or alternatively, the use of automated vaccination machines, which requires considerable investment.…”

Section: Vaccine Development and Immunization Strategiesmentioning

confidence: 99%

Challenges and Solutions to Viral Diseases of Finfish in Marine Aquaculture

et al. 2021

Self Cite

View full text Add to dashboard Cite

Aquaculture is the fastest food-producing sector in the world, accounting for one-third of global food production. As is the case with all intensive farming systems, increase in infectious diseases has adversely impacted the growth of marine fish farming worldwide. Viral diseases cause high economic losses in marine aquaculture. We provide an overview of the major challenges limiting the control and prevention of viral diseases in marine fish farming, as well as highlight potential solutions. The major challenges include increase in the number of emerging viral diseases, wild reservoirs, migratory species, anthropogenic activities, limitations in diagnostic tools and expertise, transportation of virus contaminated ballast water, and international trade. The proposed solutions to these problems include developing biosecurity policies at global and national levels, implementation of biosecurity measures, vaccine development, use of antiviral drugs and probiotics to combat viral infections, selective breeding of disease-resistant fish, use of improved diagnostic tools, disease surveillance, as well as promoting the use of good husbandry and management practices. A multifaceted approach combining several control strategies would provide more effective long-lasting solutions to reduction in viral infections in marine aquaculture than using a single disease control approach like vaccination alone.

show abstract

Effect of a novel DNA vaccine against pancreas disease caused by salmonid alphavirus subtype 3 in Atlantic salmon (Salmo salar)

Cited by 23 publications

References 34 publications

Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines

Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines

The Key Role of Nucleic Acid Vaccines for One Health

Challenges and Solutions to Viral Diseases of Finfish in Marine Aquaculture

Contact Info

Product

Resources

About